Evommune (EVMN) Revenue (2025)

Evommune (EVMN) reported Revenue of $10.0 million for Q3 2025, up 233.33% quarter-over-quarter from $3.0 million in Q1 2025.

Evommune (EVMN) Revenue (2025) Analysis & Trends

Evommune (EVMN) has 1 years of Revenue data on file, last reported at $10.0 million in Q3 2025.

  • Revenue for Q3 2025 came in at $10.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $13.0 million (changed N/A YoY), and the FY2025 annual result was $13.0 million, up 85.71% from the prior year.
  • Revenue improved to $10.0 million in Q3 2025 per EVMN's latest filing, from $3.0 million in the prior quarter.
  • Over five years, Revenue peaked at $10.0 million in Q3 2025 and troughed at $3.0 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 5.21 Mn
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 306.30 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 2.99 Bn
9 Abivax 91.96 Bn 91.96 Bn - -
10 Evommune 695.29 Mn 483.82 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 10.00 Mn
Mar 31, 2025 3.00 Mn